Mobileye quarterly earnings miss estimates, shares slide

Mobileye reported Q4 2025 adjusted EPS of $0.06 versus $0.24 expected while revenue beat at $446 million (consensus $431.85M) but declined 9% year-over-year; EyeQ chipset volumes fell 11% as Tier-1 customers ran tighter inventories. Adjusted operating margin compressed to 9% from 21% a year earlier; full-year 2026 revenue guidance of $1.9B–$1.98B topped consensus but adjusted operating income guidance of $170M–$220M (midpoint $195M) disappointed, highlighting ongoing profitability pressure despite strong cash generation ($602M operating cash, $1.8B cash balance, excluding a planned $612M Mentee Robotics outlay).

Analysis

Market structure: The Q4 EPS miss (adjusted $0.06 vs $0.24) despite a revenue beat highlights margin-led stress: EyeQ chip volumes fell ~11% and adjusted operating margin collapsed to 9% from 21% YoY, shifting bargaining power toward OEMs and encouraging cautious ordering by Tier‑1s. Direct beneficiaries in the near term are OEMs (lower input pressure) and broader AI semiconductor leaders (NVDA, TSM) that retain secular demand; direct losers are pure‑play ADAS/software names (MBLY, LAZR) and smaller Tier‑1 suppliers exposed to EyeQ destocking. Cross-asset: expect MBLY equity implied volatility to rise, small idiosyncratic spread widening in corporate credit if acquisition increases leverage, limited commodity impact, and potential modest negative demand impulse to foundry orders in the next two quarters.

Risk assessment: Tail risks include a failed integration or higher-than-expected cash outlay on the $612m Mentee Robotics deal, a regulatory AV incident triggering recalls, or a prolonged OEM destocking that delays EyeQ restocking by 2–4 quarters. Time horizons: immediate (days) — volatility and positioning adjustments; short-term (1–3 months) — Q1 shipments and Mentee close; long-term (12–24 months) — product adoption and margin normalization. Hidden dependencies: OEM inventory cycles, EV production ramps, and incentive-driven feature adoption rates; catalysts to watch are Q1 ship volumes, margin reconciliation to guidance, and any OEM reorders.

Trade implications: Tactical short risk in MBLY is justified until operating margin guidance (>=$195m midpoint) proves durable — consider a size-limited short (1–2% portfolio) or buying 3-month ATM puts if price rebounds <5% intraday; target a 15–25% downside within 3 months, stop-loss at +8%. Relative-value: pair long NVDA or TSM (2–3% long) vs short MBLY (1–1.5%) to express AI secular over ADAS margin risk through 6–12 months. For income/convexity, sell 30–60 day covered calls against existing MBLY holdings or implement a 12–18 month diagonal (buy LEAP calls Jan 2028 ATM, sell short-dated calls) to finance long exposure while collecting premium.

Contrarian angles: The market may be overstating structural demand loss — Mobileye generated $602m operating cash and ends with $1.8bn cash, enough to fund R&D and the Mentee deal; if Tier‑1 destocking reverses, EyeQ volumes could reaccelerate 15–25% YoY starting Q3, delivering >30% upside to TBV within 12–18 months. Historical parallels: cyclical ADAS inventory resets (2018–19) led to pronounced short-term hits followed by strong rebounds as OEM feature cycles resumed. Risks to the contrarian view: sustained margin erosion or integration surprises; require confirmation of sequential EyeQ shipment recovery and operating margin >12% before scaling long positions.

Key Decisions for Investors

• Initiate a tactical short position in MBLY equal to 1–2% of portfolio via equity or buy 3‑month ATM puts if MBLY rallies less than 5% intraday; set profit target 15–25% within 3 months and a strict stop-loss of +8% adverse move.
• Establish a relative-value pair: long NVDA or TSM (2–3% position) and short MBLY (1–1.5%) to capture AI secular demand vs ADAS margin risk over a 6–12 month horizon; rebalance if MBLY operating margin guidance midpoint >$195m is confirmed.
• If constructive on long-term 'Physical AI', buy Jan 2028 LEAP calls on MBLY at-the-money for a 12–24 month hold (size 1% of portfolio) financed by selling 30–60 day calls to collect premium; scale up only after two consecutive quarters of EyeQ shipment growth and operating margin >12%.
• Avoid increasing exposure to small ADAS pure-plays; redeploy 2–4% into semiconductor leaders (NVDA, TSM) that show >=10% revenue growth guidance and durable gross margins, given likely capital allocation shift and secular AI demand.